S&P/ASX 200 Index (ASX: XJO) stock Atlas Arteria (ASX: ALX) is ticking higher on Wednesday, rising 0.6% to $4.82 during early afternoon trading.
The modest gain follows a key update on a takeover approach from IFM Investors. Atlas Arteria's independent directors have formally recommended that securityholders reject IFM's hostile offer. They argue it undervalues the business and comes with significant conditions.
IFM's proposal stands at $4.75 per stapled security, which is below the current trading price, a factor that may also be supporting the share price.
Image source: Getty Images
So, what exactly did Atlas Arteria say?
The board described the bid as opportunistic, noting it comes at a time of recent market volatility and follows a period where the ASX 200 stock has traded well above the offer price over the past year.
Independent directors believe the proposal fails to reflect the true value of Atlas Arteria's global toll road portfolio and its future growth potential. The company owns and operates major infrastructure assets across North America and Europe, generating stable, inflation-linked cash flows.
Over 50 extra conditions
Another major sticking point is the structure of the offer itself. The $7 billion ASX 200 stock highlighted that IFM's takeover proposal includes more than 50 separate sub-conditions, some of which are already incapable of being satisfied. That level of conditionality introduces uncertainty and reduces the likelihood of the deal proceeding in its current form.
In a separate but related development, Atlas Arteria has issued a Right of First Offer over its interest in the Chicago Skyway. While not directly tied to the takeover bid, this move is relevant to certain conditions within IFM's proposal. It also signals the company is continuing to actively manage its asset portfolio.
Exploring asset recycling
Management also reiterated that it is exploring broader value-enhancing initiatives for investors. These include potential asset recycling and strategic options for its US operations, which could unlock additional value over time.
Chair Debbie Goodin was direct in her assessment of the bid:
This hostile, highly conditional takeover offer from IFM is opportunistic and materially undervalues Atlas Arteria. The Offer is designed to accelerate IFM's creep to effective control of Atlas Arteria without paying a fair premium to securityholders. The Independent Directors of Atlas Arteria recommend that securityholders reject the Offer. The Boards and management remain focused on continuing to deliver on the strategy to optimise company value and create value for all securityholders.
What next for the ASX 200 stock?
Atlas Arteria is now preparing a formal Target's Statement, which will include an independent expert's report and outline the board's detailed recommendation. This will be provided to investors at least 14 days before the offer closes.
Looking at recent performance, Atlas Arteria shares have rallied nearly 14% over the past month. However, over the past year, the ASX 200 stock is still down around 7%, lagging the S&P/ASX 200 Index, which has gained about 6%.
For now, the market appears to be backing the board's view that the offer undervalues the company. That could explain why the share price is holding above the bid.
